Evidence map›Paper›PMID 39587072›Full record

ArticleNature communications2024

Haploinsufficiency at the CX3CR1 locus of hematopoietic stem cells favors the appearance of microglia-like cells in the central nervous system of transplant recipients.

Annita Montepeloso, Davide Mattioli, Danilo Pellin, Marco Peviani, Pietro Genovese, Alessandra Biffi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Annita MontepelosoDana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA, USA.ORCID 0000-0003-3299-476X
Davide MattioliDana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA, USA.
Danilo PellinDana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-2647-0508
Marco PevianiDana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA, USA.
Pietro GenoveseDana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-9507-9003
Alessandra BiffiDivision of Pediatric Hematology, Oncology and Stem Cell Transplantation, University of Padua, Padua, Italy. alessandra.biffi@unipd.it.ORCID 0000-0002-4610-0870

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Transplantation of engineered hematopoietic stem/progenitor cells (HSPCs) showed curative potential in patients affected by neurometabolic diseases treated in early stage. Favoring the engraftment and maturation of the engineered HSPCs in the central nervous system (CNS) could allow enhancing further the therapeutic potential of this approach. Here we unveil that HSPCs haplo-insufficient at the Cx3cr1 (Cx3cr1

Indexed as

Central Nervous SystemCX3C Chemokine Receptor 1HaploinsufficiencyHematopoietic Stem CellsHematopoietic Stem Cell TransplantationMicrogliaAnimalsCRISPR-Cas SystemsFemaleGenetic LociGenetic TherapyHumansMaleMiceCX3C Chemokine Receptor 1CX3CR1 protein, humanCx3cr1 protein, mouse

Identifiers

PMID39587072
PMCPMC11589136

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.